Merus N.V. (MRUS)

NASDAQ: MRUS · IEX Real-Time Price · USD
26.79 -1.67 (-5.87%)
Jan 18, 2022 4:00 PM EST - Market closed
Market Cap1.14B
Revenue (ttm)43.41M
Net Income (ttm)-80.36M
Shares Out42.67M
EPS (ttm)-2.25
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume136,751
Open28.18
Previous Close28.46
Day's Range26.74 - 28.50
52-Week Range16.14 - 33.09
Beta0.97
AnalystsStrong Buy
Price Target42.67 (+59.3%)
Earnings DateNov 4, 2021

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-1...

IndustryBiotechnology
IPO DateMay 19, 2016
CEOSven Lundberg
Employees93
Stock ExchangeNASDAQ
Ticker SymbolMRUS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for Merus stock is "Strong Buy." The 12-month stock price forecast is 42.67, which is an increase of 59.26% from the latest price.

Price Target
$42.67
(59.26% upside)
Analyst Consensus: Strong Buy

News

Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Brea...

- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met

1 month ago - GlobeNewsWire

Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovati...

1 month ago - GlobeNewsWire

Merus N.V. Announces Proposed Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovati...

2 months ago - GlobeNewsWire

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 40.91% and 29.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) --  Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovat...

2 months ago - GlobeNewsWire

Will Merus N.V. (MRUS) Report Negative Q3 Earnings?

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Strength Seen in Merus N.V. (MRUS): Can Its 37.5% Jump Turn into More Strength?

Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in...

3 months ago - Zacks Investment Research

Here's Why Merus Stock Is Flying Higher Today

This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results.

3 months ago - The Motley Fool

Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual In...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovati...

3 months ago - GlobeNewsWire

Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Confer...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovat...

3 months ago - GlobeNewsWire

Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of -18.33% and 58.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Merus Announces Financial Results for the Second Quarter and Provides Business Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovati...

5 months ago - GlobeNewsWire

Earnings Preview: Merus N.V. (MRUS) Q2 Earnings Expected to Decline

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Merus to Participate in William Blair's Biotech Focus Conference 2021

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies ...

6 months ago - GlobeNewsWire

Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Onco...

-  61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date-  Encouraging early clinical activity observed, with confirmed...

7 months ago - GlobeNewsWire

Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (...

7 months ago - GlobeNewsWire

Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Cl...

-   51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date-   Encouraging early clinical activity observed, with conf...

7 months ago - GlobeNewsWire

Merus N.V. (MRUS) Moves 13% Higher: Will This Strength Last?

Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

7 months ago - Zacks Investment Research

Merus N.V. (MRUS) Reports Q1 Loss, Lags Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of -27.27% and -63.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Merus Announces Financial Results for the First Quarter and Provides Business Update

Clinical data update on zenocutuzumab selected for oral presentation at ASCO  MCLA-145 clinical update planned for 2H21  MCLA-129 first patient dosed in phase 1/2 trial  Cecile Geuijen, Ph.D., promoted ...

8 months ago - GlobeNewsWire

Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid...

Merus' Fourth Sponsored Bispecific Antibody Currently in Clinical Trials Merus' Fourth Sponsored Bispecific Antibody Currently in Clinical Trials

8 months ago - GlobeNewsWire

Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual M...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovat...

8 months ago - GlobeNewsWire

Merus N.V. (MRUS) Reports Q4 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of -26.23% and 11.19%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update

Clinical data and program update planned for lead program zenocutuzumab (“Zeno”) in 2Q 2021

10 months ago - GlobeNewsWire

Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovat...

10 months ago - GlobeNewsWire